News for Molecular Partners AG (MOLN.SW)

Molecular Partners (MOLN) has announced the presentation of significant preclinical findings at the American Association for Cancer Research annual meeting 2025

Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readou

\n Molecular Partners (MOLN) shareholders approved all board proposals at the Annual General Meeting. The company reported a net loss of CHF 50.6 million f

**media[597168]**

After losing some value lately, a hammer chart pattern has been formed for Molecular Partners AG Sponsored ADR (MOLN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Revenue: CHF5 million in 2024, exclusively from the Novartis collaboration.Operating Expenses: CHF66 million, within the guidance range of CHF65 million to CHF

Mar 07, 2025 / 01:00PM GMTOperator Good morning, and welcome to the Molecular Partners fourth quarter and full year 2024 results call. (Operator Instructions).

Molecular Partners AG (NASDAQ:MOLN) Q4 2024 Earnings Conference Call March 7, 2025 8:00 AM ETCompany ParticipantsMichael Tobias Stumpp - EVP ProjectsPatrick...

**media[559663]**

Participation in fireside chats at TD Cowen and Leerink healthcare conferencesCall on 2024 financial results on March 7 at 2.00 pm CET (8.00 am ET) ZURICH-SCHL

Molecular Partners' DARPin platform shows promise, but future funding is uncertain. Learn why MOLN stock could be a risky, but promising buy.

Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025Mesothelin named as second target in Radio-DARPin pipel

New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to tenEx

**media[494978]**

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; MOLN), a clinical-stage biotech company

The consensus price target hints at an 80.7% upside potential for Molecular Partners AG Sponsored ADR (MOLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic activity

**media[457118]**